相关实验视频
Updated: Jan 7, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
869
心脏病综合征中的肥胖:管理机会和挑战
Allison Reaves1, Emily Jaffe2, Wendy McCallum3
1Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA, 02111, USA.
Current hypertension reports
|December 27, 2025
概括
肥胖,心力衰竭与保存的喷射分数,和慢性病 (CKD) 有关. 新的肥胖治疗方法对心血管和脏有好处,改善了这些复杂疾病的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 全球肥胖患病率正在上升,增加心血管疾病和慢性病 (CKD) 的风险.
- 肥胖,心力衰竭与保留喷射分数 (HFpEF) 和CKD共享复杂的病理生理联系,包括心脏病综合征.
- 脂肪细胞有助于脏保留和体积过载,这是心脏脏综合征的关键因素.
研究的目的:
- 审查对同时存在的肥胖,HFpEF和CKD的诊断和管理策略.
- 检查肥胖治疗对患有这些疾病的患者长期健康结果的影响.
主要方法:
- 关于肥胖,HFpEF和CKD之间的相互作用的当前文献的综述.
- 关于新兴肥胖治疗疗法的疗效的证据分析.
主要成果:
- 新兴证据通过脂肪细胞介导的效应将肥胖,HFpEF和CKD病理生理学联系起来.
- 类似葡萄糖类-1受体激动剂在患有肥胖和糖尿病,CKD和HFpEF等并发症的患者中显示出心血管和的益处.
- 有效的肥胖管理对于改善并发性HFpEF和CKD患者的治疗结果至关重要.
结论:
- 综合,多学科管理和共享决策对于优化患者护理至关重要.
- 改善对肥胖的识别和治疗是管理心脏病综合征的关键.
- 新型肥胖药物疗法为心血管和脏健康提供了显著的好处.
相关概念视频
Chronic Kidney Disease IV: Nursing Management
287
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
287
Heart Failure VI: Adjunct Therapies
233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Cardiomyopathy VI: Nursing Management
289
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
289
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
Chronic Kidney Disease III: Interprofessional Care
319
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
319
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
218
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
218

